Tests how the body absorbs and clears AZD1390 in adults with advanced solid cancers
Tests how the body processes AZD1390 in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: Human ADME Study of [14C]-AZD1390
Key facts
- Where
- Guildford and Liverpool, United KingdomSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07643870, who can take part
Where in United Kingdom
- GuildfordGuildford, United KingdomNo longer taking part
- LiverpoolLiverpool, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07643870
- Record updated
- 12 June 2026
- Original description
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.Read full original descriptionShow less
A Phase I, Open-label Study to Assess the Absorption, Distribution, Metabolism, and Excretion (ADME) of AZD1390 After a Single Oral Dose of [14C]-AZD1390 in Participants With Advanced Solid Malignancies
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
Inclusion: Participants with Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, no active anticancer treatment,; ECOG performance status of 0 or 1 with no deterioration over the 2 weeks,; Predicted life expectancy ≥ 12 weeks,; Adequate organ and marrow function,; Creatinine clearance ≥ 50 mL/min,; Regular bowel movements,; No cancer-associated cachexia (weight loss).
Exclusion: Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection; Persistent toxicities (CTCAE Grade ≥ 2), excluding alopecia, caused by previous anticancer therapy,; History of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment,; History or presence of clinically significant hepatic disease,; History of epileptic disorder or any seizure history unrelated to tumour,; History of MDS/AML or with features suggestive of MDS/AML,; Predisposition to bleeding; History of persisting (> 2 weeks) severe cytopenia; History of another primary malignancy; History or presence of myopathy or raised CK > 5 × ULN at screening,; Spinal cord compression or brain metastases for at least 4 weeks.